CYP4F2: A Potential Drug Target for Heart Disease and Cancer (G8529)

Target Name: CYP4F2

NCBI ID: G8529

CYP4F2: A Potential Drug Target for Heart Disease and Cancer

CYP4F2, also known as 20-hydroxyeicosatetraenoic acid synthase, is a gene that codes for a protein in the cytoplasm of all living cells. The protein produced by this gene is involved in the synthesis of a fatty acid called 20-hydroxyeicosatetraenoic acid, which is a key component of cell membranes.

Research has shown that CYP4F2 is highly expressed in various tissues, including the brain, heart, liver, and muscle. It is also expressed in the placenta, which supports the development and growth of new fetuses. Additionally, it has been shown to be highly expressed in cancer cells, which may have implications for the development and progression of cancer.

One of the main functions of CYP4F2 is its role in the synthesis of 20-hydroxyeicosatetraenoic acid, which is an essential component of cell membranes. This protein is vital for maintaining the structural integrity and fluid balance of cells, as well as regulating various cellular processes.

CYP4F2 has also been shown to be involved in the regulation of inflammation and immune response. It has been shown to play a key role in the production of pro-inflammatory cytokines, which can contribute to the development of inflammatory diseases such as heart disease and cancer.

Additionally, CYP4F2 has been shown to be involved in the regulation of cell death and metabolism. It has been shown to play a key role in the production of cell death signaling molecules, which can contribute to the development of various diseases such as neurodegenerative diseases.

Given its involvement in the synthesis of 20-hydroxyeicosatetraenoic acid and its role in the regulation of various cellular processes, CYP4F2 may be a drug target or biomarker for various diseases. For example, it may be a target for treating heart disease, as the production of 20-hydroxyeicosatetraenoic acid has been shown to be increased in individuals with heart disease. Additionally, CYP4F2 may be a biomarker for cancer, as it has been shown to be highly expressed in cancer cells.

Overall, CYP4F2 is a gene that has significant implications for the development and treatment of various diseases. Further research is needed to fully understand its role in cellular processes and its potential as a drug target or biomarker.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 2

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, eicosanoids and vitamins (PubMed:18577768, PubMed:10833273, PubMed:10660572, PubMed:11997390, PubMed:17341693, PubMed:18574070). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase). Catalyzes predominantly the oxidation of the terminal carbon (omega-oxidation) of long- and very long-chain fatty acids. Displays high omega-hydroxylase activity toward polyunsaturated fatty acids (PUFAs) (PubMed:18577768). Participates in the conversion of arachidonic acid to omega-hydroxyeicosatetraenoic acid (20-HETE), a signaling molecule acting both as vasoconstrictive and natriuretic with overall effect on arterial blood pressure (PubMed:10660572, PubMed:17341693, PubMed:18574070). Plays a role in the oxidative inactivation of eicosanoids, including both pro-inflammatory and anti-inflammatory mediators such as leukotriene B4 (LTB4), lipoxin A4 (LXA4), and several HETEs (PubMed:8026587, PubMed:9799565, PubMed:10833273, PubMed:10660572, PubMed:17341693, PubMed:18574070, PubMed:18577768). Catalyzes omega-hydroxylation of 3-hydroxy fatty acids (PubMed:18065749). Converts monoepoxides of linoleic acid leukotoxin and isoleukotoxin to omega-hydroxylated metabolites (PubMed:15145985). Contributes to the degradation of very long-chain fatty acids (VLCFAs) by catalyzing successive omega-oxidations and chain shortening (PubMed:16547005, PubMed:18182499). Plays an important role in vitamin metabolism by chain shortening. Catalyzes omega-hydroxylation of the phytyl chain of tocopherols (forms of vitamin E), with preference for gamma-tocopherols over alpha-tocopherols, thus promoting retention of alpha-tocopherols in tissues (PubMed:11997390). Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation (PubMed:19297519, PubMed:24138531)

More Common Targets